Biologicals

Meningococcal

Recommendations to assure the quality, safety and efficacy of Group A Meningococcal Conjugate vaccines

ECBS 2006

Recommendations for the production and control of group C meningococcal conjugate vaccines, TRS 926, Annex 3

Recommendations for the production and control of Meningococcal group C conjugate vaccines, TRS 924, 2004, Annex 2

Requirements for Meningococcal Polysaccharide vaccine (Amendment 1999) TRS 904, 2002 Annex 2

Requirements for meningococcal polysaccharide vaccine, Addendum 1980, TRS 658 Annex 6

Requirements for Meningococcal Polysaccharide vaccine: Adopted 1975, TRS 594, Annex 2

UPCOMING EVENTS


  • WHO Informal Consultation on Regulatory considerations for evaluation of Ebola Vaccines intended for emergency use, WHO/HQ Geneva, Switzerland, 18-19 March 2015
  • WHO Informal Consultation on Stability Evaluation of Vaccines for use in a Controlled Temperature Chain, WHO/HQ Geneva, Switzerland, 24–26 March 2015
  • WHO Informal Consultation on Amendment for Similar Biotherapeutic products of monoclonal antibodies, WHO/HQ Geneva, Switzerland, 27–28 April 2015
  • WHO Informal Consultation on Regulatory risk assessment for biotherapeutic products, WHO/HQ Geneva, Switzerland, 29–30 April 2015

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971